Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 14/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | FBP1 | P09467 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20680203 | 0.86 | EGFR (0.67) | CD38EGFRKDRAURKAFBP1 | |
| SCHEMBL20680404 | 0.83 | EGFR (0.52) | CD38EGFRKDRAURKAFBP1 | |
| SCHEMBL6188729 | 0.80 | EGFR (0.77) | CD38EGFRKDRAURKAFBP1 | |
| Hydrochloric Acid SCHEMBL6190330 | 0.79 | EGFR (0.75) | CD38EGFRKDRAURKAFBP1 | |
| SCHEMBL20680261 | 0.78 | CD38 (1.00) | CD38EGFRERBB2GRM1 | |
| SCHEMBL12788058 | 0.78 | EGFR (0.72) | EGFRKDRAURKAFBP1ERBB2 | |
| SCHEMBL19762918 | 0.78 | EGFR (0.69) | CD38EGFRKDRAURKAFBP1 | |
| SCHEMBL28119911 | 0.77 | EGFR (0.70) | EGFRKDRAURKAFBP1ERBB2 | |
| Hydrochloric Acid SCHEMBL7486055 | 0.76 | EGFR (0.69) | EGFRKDRAURKAFBP1ERBB2 | |
| SCHEMBL8213640 | 0.74 | EGFR (0.85) | EGFRKDRAURKAFBP1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2021-03-25 | — | — | US | disclosed |
| EP-3658586-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2020-06-03 | — | — | EP | disclosed |
| CN-111108127-A | Compounds that specifically bind CD38 for use in the treatment of neurodegenerative and inflammatory diseases | ENCEFA公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019020643-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | CD38, TRPC1, TRPC4 | CD38 1/4885EGFR 4562/4885KDR 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.